132 related articles for article (PubMed ID: 28332573)
21. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
[TBL] [Abstract][Full Text] [Related]
22. Discovery of a broad spectrum antiproliferative agent with selectivity for DDR1 kinase: cell line-based assay, kinase panel, molecular docking, and toxicity studies.
Elkamhawy A; Park JE; Cho NC; Sim T; Pae AN; Roh EJ
J Enzyme Inhib Med Chem; 2016; 31(1):158-66. PubMed ID: 25807298
[TBL] [Abstract][Full Text] [Related]
23. In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesis.
Latham AM; Kankanala J; Fearnley GW; Gage MC; Kearney MT; Homer-Vanniasinkam S; Wheatcroft SB; Fishwick CW; Ponnambalam S
PLoS One; 2014; 9(11):e110997. PubMed ID: 25393739
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of novel oxindole-based RTK inhibitors as anti-cancer agents.
Chen G; Weng Q; Fu L; Wang Z; Yu P; Liu Z; Li X; Zhang H; Liang G
Bioorg Med Chem; 2014 Dec; 22(24):6953-60. PubMed ID: 25456085
[TBL] [Abstract][Full Text] [Related]
25. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents.
Aziz MA; Serya RA; Lasheen DS; Abdel-Aziz AK; Esmat A; Mansour AM; Singab AN; Abouzid KA
Sci Rep; 2016 Apr; 6():24460. PubMed ID: 27080011
[TBL] [Abstract][Full Text] [Related]
27. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
28. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
Shi L; Zhou J; Wu J; Cao J; Shen Y; Zhou H; Li X
Bioorg Med Chem; 2016 Apr; 24(8):1840-52. PubMed ID: 26968648
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
30. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
[TBL] [Abstract][Full Text] [Related]
31. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
Kissau L; Stahl P; Mazitschek R; Giannis A; Waldmann H
J Med Chem; 2003 Jul; 46(14):2917-31. PubMed ID: 12825933
[TBL] [Abstract][Full Text] [Related]
32. Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.
Dai Y; Hartandi K; Ji Z; Ahmed AA; Albert DH; Bauch JL; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Harris CM; Hickman D; Guo J; Li J; Marcotte PA; Marsh KC; Moskey MD; Martin RL; Olson AM; Osterling DJ; Pease LJ; Soni NB; Stewart KD; Stoll VS; Tapang P; Reuter DR; Davidsen SK; Michaelides MR
J Med Chem; 2007 Apr; 50(7):1584-97. PubMed ID: 17343372
[TBL] [Abstract][Full Text] [Related]
33. Discovery of new 4-alkoxyquinazoline-based derivatives as potent VEGFR2 inhibitors.
Yin Y; Sha S; Wang YT; Wu X; Wang SF; Qiao F; Lv PC; Zhu HL
Chem Biol Drug Des; 2015 Nov; 86(5):1323-9. PubMed ID: 26032487
[TBL] [Abstract][Full Text] [Related]
34. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of novel oxazolo[5,4-d]pyrimidines as potent VEGFR-2 inhibitors.
Deng YH; Xu D; Su YX; Cheng YJ; Yang YL; Wang XY; Zhang J; You QD; Sun LP
Chem Biodivers; 2015 Apr; 12(4):528-37. PubMed ID: 25879498
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
37. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel anti-angiogenesis agents. Part 11: Development of PROTACs based on active molecules with potency of promoting vascular normalization.
Shan Y; Si R; Wang J; Zhang Q; Li J; Ma Y; Zhang J
Eur J Med Chem; 2020 Nov; 205():112654. PubMed ID: 32750566
[TBL] [Abstract][Full Text] [Related]
39. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
40. Discovery of novel taspine derivatives as antiangiogenic agents.
Zhang J; Zhang Y; Zhang S; Wang S; He L
Bioorg Med Chem Lett; 2010 Jan; 20(2):718-21. PubMed ID: 20006929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
